| Year |
Citation |
Score |
| 2024 |
Chong JR, Chai YL, Yam ATY, Hilal S, Vrooman H, Venketasubramanian N, Blennow K, Zetterberg H, Ashton NJ, Chen CP, Lai MKP. Association of plasma GFAP with elevated brain amyloid is dependent on severity of white matter lesions in an Asian cognitively impaired cohort. Alzheimer's & Dementia (Amsterdam, Netherlands). 16: e12576. PMID 38605996 DOI: 10.1002/dad2.12576 |
0.366 |
|
| 2024 |
Kac PR, González-Ortiz F, Emeršič A, Dulewicz M, Koutarapu S, Turton M, An Y, Smirnov D, Kulczyńska-Przybik A, Varma VR, Ashton NJ, Montoliu-Gaya L, Camporesi E, Winkel I, Paradowski B, et al. Plasma p-tau212 antemortem diagnostic performance and prediction of autopsy verification of Alzheimer's disease neuropathology. Nature Communications. 15: 2615. PMID 38521766 DOI: 10.1038/s41467-024-46876-7 |
0.448 |
|
| 2024 |
Brum WS, Cullen NC, Therriault J, Janelidze S, Rahmouni N, Stevenson J, Servaes S, Benedet AL, Zimmer ER, Stomrud E, Palmqvist S, Zetterberg H, Frisoni GB, Ashton NJ, Blennow K, et al. A blood-based biomarker workflow for optimal tau-PET referral in memory clinic settings. Nature Communications. 15: 2311. PMID 38486040 DOI: 10.1038/s41467-024-46603-2 |
0.42 |
|
| 2024 |
Therriault J, Schindler SE, Salvadó G, Pascoal TA, Benedet AL, Ashton NJ, Karikari TK, Apostolova L, Murray ME, Verberk I, Vogel JW, La Joie R, Gauthier S, Teunissen C, Rabinovici GD, et al. Biomarker-based staging of Alzheimer disease: rationale and clinical applications. Nature Reviews. Neurology. PMID 38429551 DOI: 10.1038/s41582-024-00942-2 |
0.507 |
|
| 2024 |
Bastgen T, Evers J, Oedekoven C, Weide C, Herzog L, Ashton N, Zetterberg H, Blennow K, Albus A, Vidovic N, Kraff O, Deuschl C, Dodel R, Ross JA. Repetitive head injuries in German American football players do not change blood-based biomarker candidates for CTE during a single season. Neurological Research and Practice. 6: 13. PMID 38419110 DOI: 10.1186/s42466-024-00307-6 |
0.437 |
|
| 2024 |
Lantero-Rodriguez J, Salvadó G, Snellman A, Montoliu-Gaya L, Brum WS, Benedet AL, Mattsson-Carlgren N, Tideman P, Janelidze S, Palmqvist S, Stomrud E, Ashton NJ, Zetterberg H, Blennow K, Hansson O. Plasma N-terminal containing tau fragments (NTA-tau): a biomarker of tau deposition in Alzheimer's Disease. Molecular Neurodegeneration. 19: 19. PMID 38365825 DOI: 10.1186/s13024-024-00707-x |
0.506 |
|
| 2024 |
Ferrari-Souza JP, Brum WS, Hauschild LA, Da Ros LU, Ferreira PCL, Bellaver B, Leffa DT, Bieger A, Tissot C, Lussier FZ, De Bastiani MA, Povala G, Benedet AL, Therriault J, Wang YT, ... Ashton NJ, et al. Vascular risk burden is a key player in the early progression of Alzheimer's disease. Neurobiology of Aging. 136: 88-98. PMID 38335912 DOI: 10.1016/j.neurobiolaging.2023.12.008 |
0.55 |
|
| 2024 |
Nilsson J, Pichet Binette A, Palmqvist S, Brum WS, Janelidze S, Ashton NJ, Spotorno N, Stomrud E, Gobom J, Zetterberg H, Brinkmalm A, Blennow K, Hansson O. Cerebrospinal fluid biomarker panel for synaptic dysfunction in a broad spectrum of neurodegenerative diseases. Brain : a Journal of Neurology. PMID 38325331 DOI: 10.1093/brain/awae032 |
0.513 |
|
| 2024 |
Coley N, Zetterberg H, Cantet C, Guyonnet S, Ashton NJ, Vellas B, Blennow K, Andrieu S. Plasma p-tau181 as an outcome and predictor of multidomain intervention effects: a secondary analysis of a randomised, controlled, dementia prevention trial. The Lancet. Healthy Longevity. 5: e120-e130. PMID 38310892 DOI: 10.1016/S2666-7568(23)00255-6 |
0.502 |
|
| 2024 |
Huber H, Blennow K, Zetterberg H, Boada M, Jeromin A, Weninger H, Nuñez-Llaves R, Aguilera N, Ramis M, Simrén J, Nilsson J, Lantero-Rodriguez J, Orellana A, García-Gutiérrez F, Morató X, ... Ashton NJ, et al. Biomarkers of Alzheimer's disease and neurodegeneration in dried blood spots-A new collection method for remote settings. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 38284555 DOI: 10.1002/alz.13697 |
0.538 |
|
| 2024 |
Arslan B, Zetterberg H, Ashton NJ. Blood-based biomarkers in Alzheimer's disease - moving towards a new era of diagnostics. Clinical Chemistry and Laboratory Medicine. PMID 38253262 DOI: 10.1515/cclm-2023-1434 |
0.567 |
|
| 2024 |
Ashton NJ, Brum WS, Di Molfetta G, Benedet AL, Arslan B, Jonaitis E, Langhough RE, Cody K, Wilson R, Carlsson CM, Vanmechelen E, Montoliu-Gaya L, Lantero-Rodriguez J, Rahmouni N, Tissot C, et al. Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology. Jama Neurology. PMID 38252443 DOI: 10.1001/jamaneurol.2023.5319 |
0.536 |
|
| 2024 |
Mendes AJ, Ribaldi F, Lathuiliere A, Ashton NJ, Janelidze S, Zetterberg H, Scheffler M, Assal F, Garibotto V, Blennow K, Hansson O, Frisoni GB. Head-to-head study of diagnostic accuracy of plasma and cerebrospinal fluid p-tau217 versus p-tau181 and p-tau231 in a memory clinic cohort. Journal of Neurology. PMID 38195896 DOI: 10.1007/s00415-023-12148-5 |
0.393 |
|
| 2024 |
Therriault J, Woo MS, Salvadó G, Gobom J, Karikari TK, Janelidze S, Servaes S, Rahmouni N, Tissot C, Ashton NJ, Benedet AL, Montoliu-Gaya L, Macedo AC, Lussier FZ, Stevenson J, et al. Comparison of immunoassay- with mass spectrometry-derived p-tau quantification for the detection of Alzheimer's disease pathology. Molecular Neurodegeneration. 19: 2. PMID 38185677 DOI: 10.1186/s13024-023-00689-2 |
0.367 |
|
| 2024 |
Lantero-Rodriguez J, Montoliu-Gaya L, Benedet AL, Vrillon A, Dumurgier J, Cognat E, Brum WS, Rahmouni N, Stevenson J, Servaes S, Therriault J, Becker B, Brinkmalm G, Snellman A, Huber H, ... ... Ashton NJ, et al. CSF p-tau205: a biomarker of tau pathology in Alzheimer's disease. Acta Neuropathologica. 147: 12. PMID 38184490 DOI: 10.1007/s00401-023-02659-w |
0.423 |
|
| 2023 |
Kac PR, González-Ortiz F, Emeršič A, Dulewicz M, Koutarapu S, Turton M, An Y, Smirnov D, Kulczyńska-Przybik A, Varma V, Ashton NJ, Montoliu-Gaya L, Camporesi E, Winkel I, Paradowski B, et al. Plasma p-tau212: antemortem diagnostic performance and prediction of autopsy verification of Alzheimer's disease neuropathology. Medrxiv : the Preprint Server For Health Sciences. PMID 38168323 DOI: 10.1101/2023.12.11.23299806 |
0.449 |
|
| 2023 |
Montoliu-Gaya L, Alosco ML, Yhang E, Tripodis Y, Sconzo D, Ally M, Grötschel L, Ashton NJ, Lantero-Rodriguez J, Sauer M, Gomes B, Nilsson J, Brinkmalm G, Sugarman MA, Aparicio HJ, et al. Optimal blood tau species for the detection of Alzheimer's disease neuropathology: an immunoprecipitation mass spectrometry and autopsy study. Acta Neuropathologica. 147: 5. PMID 38159140 DOI: 10.1007/s00401-023-02660-3 |
0.517 |
|
| 2023 |
Brum WS, Docherty KF, Ashton NJ, Zetterberg H, Hansson O, McMurray JJV, Blennow K. Effect of Neprilysin Inhibition on Alzheimer Disease Plasma Biomarkers: A Secondary Analysis of a Randomized Clinical Trial. Jama Neurology. PMID 38109077 DOI: 10.1001/jamaneurol.2023.4719 |
0.436 |
|
| 2023 |
Mattsson-Carlgren N, Collij LE, Stomrud E, Pichet Binette A, Ossenkoppele R, Smith R, Karlsson L, Lantero-Rodriguez J, Snellman A, Strandberg O, Palmqvist S, Ashton NJ, Blennow K, Janelidze S, Hansson O. Plasma Biomarker Strategy for Selecting Patients With Alzheimer Disease for Antiamyloid Immunotherapies. Jama Neurology. PMID 38048096 DOI: 10.1001/jamaneurol.2023.4596 |
0.525 |
|
| 2023 |
Woo MS, Nilsson J, Therriault J, Rahmouni N, Brinkmalm A, Benedet AL, Ashton NJ, Macedo AC, Servaes S, Wang YT, Tissot C, Arias JF, Hosseini SA, Chamoun M, Lussier FZ, et al. 14-3-3 [Formula: see text]-reported early synaptic injury in Alzheimer's disease is independently mediated by sTREM2. Journal of Neuroinflammation. 20: 278. PMID 38001539 DOI: 10.1186/s12974-023-02962-z |
0.411 |
|
| 2023 |
Wang YT, Therriault J, Servaes S, Tissot C, Rahmouni N, Macedo AC, Fernandez-Arias J, Mathotaarachchi SS, Benedet AL, Stevenson J, Ashton NJ, Lussier FZ, Pascoal TA, Zetterberg H, Rajah MN, et al. Sex-specific modulation of amyloid-β on tau phosphorylation underlies faster tangle accumulation in females. Brain : a Journal of Neurology. PMID 37988283 DOI: 10.1093/brain/awad397 |
0.386 |
|
| 2023 |
Brum WS, Ashton NJ, Simrén J, di Molfetta G, Karikari TK, Benedet AL, Zimmer ER, Lantero-Rodriguez J, Montoliu-Gaya L, Jeromin A, Aarsand AK, Bartlett WA, Calle PF, Coşkun A, Díaz-Garzón J, et al. Biological variation estimates of Alzheimer's disease plasma biomarkers in healthy individuals. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 37985230 DOI: 10.1002/alz.13518 |
0.512 |
|
| 2023 |
Tan K, Alpaugh M, Ashton NJ, Chouinard S, Barker RA, Blennow K, Zetterberg H, Cicchetti F, Benedet AL. Plasma GFAP and its association with disease severity in Huntington's disease. Journal of Neurology. PMID 37979092 DOI: 10.1007/s00415-023-12109-y |
0.354 |
|
| 2023 |
Gonzalez-Ortiz F, Ferreira PCL, González-Escalante A, Montoliu-Gaya L, Ortiz-Romero P, Kac PR, Turton M, Kvartsberg H, Ashton NJ, Zetterberg H, Harrison P, Bellaver B, Povala G, Villemagne VL, Pascoal TA, et al. A novel ultrasensitive assay for plasma p-tau217: Performance in individuals with subjective cognitive decline and early Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 37975513 DOI: 10.1002/alz.13525 |
0.536 |
|
| 2023 |
Vrillon A, Ashton NJ, Karikari TK, Götze K, Cognat E, Dumurgier J, Lilamand M, Zetterberg H, Blennow K, Paquet C. Comparison of CSF and plasma NfL and pNfH for Alzheimer's disease diagnosis: a memory clinic study. Journal of Neurology. PMID 37950758 DOI: 10.1007/s00415-023-12066-6 |
0.535 |
|
| 2023 |
Woo MS, Tissot C, Lantero-Rodriguez J, Snellman A, Therriault J, Rahmouni N, Macedo AC, Servaes S, Wang YT, Arias JF, Hosseini SA, Chamoun M, Lussier FZ, Benedet AL, Ashton NJ, et al. Plasma pTau-217 and N-terminal tau (NTA) enhance sensitivity to identify tau PET positivity in amyloid-β positive individuals. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 37920945 DOI: 10.1002/alz.13528 |
0.399 |
|
| 2023 |
Ally M, Sugarman MA, Zetterberg H, Blennow K, Ashton NJ, Karikari TK, Aparicio HJ, Frank B, Tripodis Y, Martin B, Palmisano JN, Steinberg EG, Simkin I, Farrer LA, Jun GR, et al. Cross-sectional and longitudinal evaluation of plasma glial fibrillary acidic protein to detect and predict clinical syndromes of Alzheimer's disease. Alzheimer's & Dementia (Amsterdam, Netherlands). 15: e12492. PMID 37885919 DOI: 10.1002/dad2.12492 |
0.551 |
|
| 2023 |
Gonzalez-Ortiz F, Ferreira PCL, Gonzalez A, Montoliu-Gaya L, Ortiz-Romero P, Kac PR, Turton M, Kvartsberg H, Ashton NJ, Zetterberg H, Harrison P, Bellaver B, Povala G, Villemagne VL, Pascoal TA, et al. A novel ultrasensitive assay for plasma p-tau217: performance in individuals with subjective cognitive decline and early Alzheimer's disease. Medrxiv : the Preprint Server For Health Sciences. PMID 37873312 DOI: 10.1101/2023.09.26.23296134 |
0.53 |
|
| 2023 |
Ferrari-Souza JP, Bellaver B, Ferreira PCL, Benedet AL, Povala G, Lussier FZ, Leffa DT, Therriault J, Tissot C, Soares C, Wang YT, Chamoun M, Servaes S, Macedo AC, Vermeiren M, ... ... Ashton NJ, et al. APOEε4 potentiates amyloid β effects on longitudinal tau pathology. Nature Aging. PMID 37749258 DOI: 10.1038/s43587-023-00490-2 |
0.485 |
|
| 2023 |
Chiotis K, Johansson C, Rodriguez-Vieitez E, Ashton NJ, Blennow K, Zetterberg H, Graff C, Nordberg A. Tracking reactive astrogliosis in autosomal dominant and sporadic Alzheimer's disease with multi-modal PET and plasma GFAP. Molecular Neurodegeneration. 18: 60. PMID 37697307 DOI: 10.1186/s13024-023-00647-y |
0.47 |
|
| 2023 |
Pelkmans W, Shekari M, Brugulat-Serrat A, Sánchez-Benavides G, Minguillón C, Fauria K, Molinuevo JL, Grau-Rivera O, González Escalante A, Kollmorgen G, Carboni M, Ashton NJ, Zetterberg H, Blennow K, Suarez-Calvet M, et al. Astrocyte biomarkers GFAP and YKL-40 mediate early Alzheimer's disease progression. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 37690071 DOI: 10.1002/alz.13450 |
0.523 |
|
| 2023 |
Yuan J, Pedrini S, Thota R, Doecke J, Chatterjee P, Sohrabi HR, Teunissen CE, Verberk IMW, Stoops E, Vanderstichele H, Meloni BP, Mitchell C, Rainey-Smith S, Goozee K, Tai ACP, ... Ashton N, et al. Elevated plasma sclerostin is associated with high brain amyloid-β load in cognitively normal older adults. Npj Aging. 9: 17. PMID 37666862 DOI: 10.1038/s41514-023-00114-4 |
0.56 |
|
| 2023 |
Brum WS, Cullen NC, Janelidze S, Ashton NJ, Zimmer ER, Therriault J, Benedet AL, Rahmouni N, Tissot C, Stevenson J, Servaes S, Triana-Baltzer G, Kolb HC, Palmqvist S, Stomrud E, et al. A two-step workflow based on plasma p-tau217 to screen for amyloid β positivity with further confirmatory testing only in uncertain cases. Nature Aging. PMID 37653254 DOI: 10.1038/s43587-023-00471-5 |
0.512 |
|
| 2023 |
Ferreira PCL, Therriault J, Tissot C, Ferrari-Souza JP, Benedet AL, Povala G, Bellaver B, Leffa DT, Brum WS, Lussier FZ, Bezgin G, Servaes S, Vermeiren M, Macedo AC, Cabrera A, ... ... Ashton NJ, et al. Plasma p-tau231 and p-tau217 inform on tau tangles aggregation in cognitively impaired individuals. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 37534889 DOI: 10.1002/alz.13393 |
0.459 |
|
| 2023 |
Erickson P, Simrén J, Brum WS, Ennis GE, Kollmorgen G, Suridjan I, Langhough R, Jonaitis EM, Van Hulle CA, Betthauser TJ, Carlsson CM, Asthana S, Ashton NJ, Johnson SC, Shaw LM, et al. Prevalence and Clinical Implications of a β-Amyloid-Negative, Tau-Positive Cerebrospinal Fluid Biomarker Profile in Alzheimer Disease. Jama Neurology. PMID 37523162 DOI: 10.1001/jamaneurol.2023.2338 |
0.399 |
|
| 2023 |
Sanchez-Rodriguez LM, Bezgin G, Carbonell F, Therriault J, Fernandez-Arias J, Servaes S, Rahmouni N, Tissot C, Stevenson J, Karikari TK, Ashton NJ, Benedet AL, Zetterberg H, Blennow K, Triana-Baltzer G, et al. Revealing the combined roles of Aβ and tau in Alzheimer's disease via a pathophysiological activity decoder. Biorxiv : the Preprint Server For Biology. PMID 37502947 DOI: 10.1101/2023.02.21.529377 |
0.523 |
|
| 2023 |
Ashton NJ, Brum WS, Di Molfetta G, Benedet AL, Arslan B, Jonatis E, Langhough RE, Cody K, Wilson R, Carlsson CM, Vanmechelen E, Montoliu-Gaya L, Lantero-Rodriguez J, Rahmouni N, Tissot C, et al. Diagnostic accuracy of the plasma ALZpath pTau217 immunoassay to identify Alzheimer's disease pathology. Medrxiv : the Preprint Server For Health Sciences. PMID 37502842 DOI: 10.1101/2023.07.11.23292493 |
0.589 |
|
| 2023 |
Assogna M, Premi E, Gazzina S, Benussi A, Ashton NJ, Zetterberg H, Blennow K, Gasparotti R, Padovani A, Tadayon E, Romanella S, Sprugnoli G, Pascual-Leone A, Di Lorenzo F, Koch G, et al. Association of Choroid Plexus Volume With Serum Biomarkers, Clinical Features, and Disease Severity in Patients With Frontotemporal Lobar Degeneration Spectrum. Neurology. PMID 37500561 DOI: 10.1212/WNL.0000000000207600 |
0.328 |
|
| 2023 |
Bucci M, Bluma M, Savitcheva I, Ashton NJ, Chiotis K, Matton A, Kivipelto M, Di Molfetta G, Blennow K, Zetterberg H, Nordberg A. Profiling of plasma biomarkers in the context of memory assessment in a tertiary memory clinic. Translational Psychiatry. 13: 268. PMID 37491358 DOI: 10.1038/s41398-023-02558-4 |
0.541 |
|
| 2023 |
Yakoub Y, Ashton NJ, Strikwerda-Brown C, Montoliu-Gaya L, Karikari TK, Kac PR, Gonzalez-Ortiz F, Gallego-Rudolf J, Meyer PF, St-Onge F, Schöll M, Soucy JP, Breitner JCS, Zetterberg H, Blennow K, et al. Longitudinal blood biomarker trajectories in preclinical Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 37294682 DOI: 10.1002/alz.13318 |
0.593 |
|
| 2023 |
Snellman A, Ekblad LL, Ashton NJ, Karikari TK, Lantero-Rodriguez J, Pietilä E, Koivumäki M, Helin S, Karrasch M, Zetterberg H, Blennow K, Rinne JO. Head-to-head comparison of plasma p-tau181, p-tau231 and glial fibrillary acidic protein in clinically unimpaired elderly with three levels of APOE4-related risk for Alzheimer's disease. Neurobiology of Disease. 106175. PMID 37268240 DOI: 10.1016/j.nbd.2023.106175 |
0.527 |
|
| 2023 |
Bellaver B, Povala G, Ferreira PCL, Ferrari-Souza JP, Leffa DT, Lussier FZ, Benedet AL, Ashton NJ, Triana-Baltzer G, Kolb HC, Tissot C, Therriault J, Servaes S, Stevenson J, Rahmouni N, et al. Astrocyte reactivity influences amyloid-β effects on tau pathology in preclinical Alzheimer's disease. Nature Medicine. PMID 37248300 DOI: 10.1038/s41591-023-02380-x |
0.508 |
|
| 2023 |
Bilgel M, An Y, Walker KA, Moghekar AR, Ashton NJ, Kac PR, Karikari TK, Blennow K, Zetterberg H, Jedynak BM, Thambisetty M, Ferrucci L, Resnick SM. Longitudinal changes in Alzheimer's-related plasma biomarkers and brain amyloid. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 37216632 DOI: 10.1002/alz.13157 |
0.494 |
|
| 2023 |
Montoliu-Gaya L, Benedet AL, Tissot C, Vrillon A, Ashton NJ, Brum WS, Lantero-Rodriguez J, Stevenson J, Nilsson J, Sauer M, Rahmouni N, Brinkmalm G, Lussier FZ, Pascoal TA, Skoog I, et al. Mass spectrometric simultaneous quantification of tau species in plasma shows differential associations with amyloid and tau pathologies. Nature Aging. PMID 37198279 DOI: 10.1038/s43587-023-00405-1 |
0.495 |
|
| 2023 |
Sunde AL, Alsnes IV, Aarsland D, Ashton NJ, Tovar-Rios DA, De Santis G, Blennow K, Zetterberg H, Kjosavik SR. Preanalytical stability of plasma biomarkers for Alzheimer's disease pathology. Alzheimer's & Dementia (Amsterdam, Netherlands). 15: e12439. PMID 37192842 DOI: 10.1002/dad2.12439 |
0.494 |
|
| 2023 |
Lantero-Rodriguez J, Tissot C, Snellman A, Servaes S, Benedet AL, Rahmouni N, Montoliu-Gaya L, Therriault J, Brum WS, Stevenson J, Lussier FZ, Bezgin G, Macedo AC, Chamoun M, Mathotaarachi SS, ... ... Ashton NJ, et al. Plasma and CSF concentrations of N-terminal tau fragments associate with in vivo neurofibrillary tangle burden. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 37190913 DOI: 10.1002/alz.13119 |
0.388 |
|
| 2023 |
Lancini E, Haag L, Bartl F, Rühling M, Ashton NJ, Zetterberg H, Düzel E, Hämmerer D, Betts MJ. Cerebrospinal fluid and positron-emission tomography biomarkers for noradrenergic dysfunction in neurodegenerative diseases: a systematic review and meta-analysis. Brain Communications. 5: fcad085. PMID 37151227 DOI: 10.1093/braincomms/fcad085 |
0.466 |
|
| 2023 |
Mgaieth F, Baksh RA, Startin CM, Hamburg S, Hithersay R, Pape S, Zetterberg H, Ashton NJ, Tamayo-Elizalde M, Saini F, Idris M, Consortium TL, Strydom A. Exploring semantic verbal fluency patterns and their relationship to age and Alzheimer's disease in adults with Down syndrome. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 37114906 DOI: 10.1002/alz.13097 |
0.411 |
|
| 2023 |
Therriault J, Servaes S, Tissot C, Rahmouni N, Ashton NJ, Benedet AL, Karikari TK, Macedo AC, Lussier FZ, Stevenson J, Wang YT, Fernandez-Arias J, Stevenson A, Socualaya KQ, Haeger A, et al. Equivalence of plasma p-tau217 with cerebrospinal fluid in the diagnosis of Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 37078495 DOI: 10.1002/alz.13026 |
0.572 |
|
| 2023 |
Oeckl P, Bluma M, Bucci M, Halbgebauer S, Chiotis K, Sandebring-Matton A, Ashton NJ, Molfetta GD, Grötschel L, Kivipelto M, Blennow K, Zetterberg H, Savitcheva I, Nordberg A, Otto M. Blood β-synuclein is related to amyloid PET positivity in memory clinic patients. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 37052206 DOI: 10.1002/alz.13046 |
0.355 |
|
| 2023 |
Van Egroo M, Riphagen JM, Ashton NJ, Janelidze S, Sperling RA, Johnson KA, Yang HS, Bennett DA, Blennow K, Hansson O, Zetterberg H, Jacobs HIL. Ultra-high field imaging, plasma markers and autopsy data uncover a specific rostral locus coeruleus vulnerability to hyperphosphorylated tau. Molecular Psychiatry. 1-11. PMID 37020050 DOI: 10.1038/s41380-023-02041-y |
0.424 |
|
| 2023 |
Ferrari-Souza JP, Lussier FZ, Leffa DT, Therriault J, Tissot C, Bellaver B, Ferreira PCL, Malpetti M, Wang YT, Povala G, Benedet AL, Ashton NJ, Chamoun M, Servaes S, Bezgin G, et al. ε4 associates with microglial activation independently of Aβ plaques and tau tangles. Science Advances. 9: eade1474. PMID 37018391 DOI: 10.1126/sciadv.ade1474 |
0.46 |
|
| 2023 |
Snellman A, Ekblad LL, Tuisku J, Koivumäki M, Ashton NJ, Lantero-Rodriguez J, Karikari TK, Helin S, Bucci M, Löyttyniemi E, Parkkola R, Karrasch M, Schöll M, Zetterberg H, Blennow K, et al. APOE ε4 gene dose effect on imaging and blood biomarkers of neuroinflammation and beta-amyloid in cognitively unimpaired elderly. Alzheimer's Research & Therapy. 15: 71. PMID 37016464 DOI: 10.1186/s13195-023-01209-6 |
0.481 |
|
| 2023 |
Altomare D, Stampacchia S, Ribaldi F, Tomczyk S, Chevalier C, Poulain G, Asadi S, Bancila B, Marizzoni M, Martins M, Lathuiliere A, Scheffler M, Ashton NJ, Zetterberg H, Blennow K, et al. Plasma biomarkers for Alzheimer's disease: a field-test in a memory clinic. Journal of Neurology, Neurosurgery, and Psychiatry. PMID 37012066 DOI: 10.1136/jnnp-2022-330619 |
0.529 |
|
| 2023 |
Montoliu-Gaya L, Alcolea D, Ashton NJ, Pegueroles J, Levin J, Bosch B, Lantero-Rodriguez J, Carmona-Iragui M, Wagemann O, Balasa M, Kac PR, Barroeta I, Lladó A, Brum WS, Videla L, et al. Plasma and cerebrospinal fluid glial fibrillary acidic protein levels in adults with Down syndrome: a longitudinal cohort study. Ebiomedicine. 90: 104547. PMID 37002988 DOI: 10.1016/j.ebiom.2023.104547 |
0.418 |
|
| 2023 |
Chong JR, Hilal S, Ashton NJ, Karikari TK, Reilhac A, Vrooman H, Schöll M, Zetterberg H, Blennow K, Chen CP, Lai MKP. Brain atrophy and white matter hyperintensities are independently associated with plasma neurofilament light chain in an Asian cohort of cognitively impaired patients with concomitant cerebral small vessel disease. Alzheimer's & Dementia (Amsterdam, Netherlands). 15: e12396. PMID 36994314 DOI: 10.1002/dad2.12396 |
0.511 |
|
| 2023 |
Bellaver B, Puig-Pijoan A, Ferrari-Souza JP, Leffa DT, Lussier FZ, Ferreira PCL, Tissot C, Povala G, Therriault J, Benedet AL, Ashton NJ, Servaes S, Chamoun M, Stevenson J, Rahmouni N, et al. Blood-brain barrier integrity impacts the use of plasma amyloid-β as a proxy of brain amyloid-β pathology. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 36919582 DOI: 10.1002/alz.13014 |
0.303 |
|
| 2023 |
Salvadó G, Ossenkoppele R, Ashton NJ, Beach TG, Serrano GE, Reiman EM, Zetterberg H, Mattsson-Carlgren N, Janelidze S, Blennow K, Hansson O. Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads. Embo Molecular Medicine. e2463. PMID 36912178 DOI: 10.15252/emmm.202217123 |
0.433 |
|
| 2023 |
Lantero-Rodriguez J, Vrillon A, Fernández-Lebrero A, Ortiz-Romero P, Snellman A, Montoliu-Gaya L, Brum WS, Cognat E, Dumurgier J, Puig-Pijoan A, Navalpotro-Gómez I, García-Escobar G, Karikari TK, Vanmechelen E, Ashton NJ, et al. Clinical performance and head-to-head comparison of CSF p-tau235 with p-tau181, p-tau217 and p-tau231 in two memory clinic cohorts. Alzheimer's Research & Therapy. 15: 48. PMID 36899441 DOI: 10.1186/s13195-023-01201-0 |
0.381 |
|
| 2023 |
Ferreira P, Ferrari-Souza JP, Tissot C, Bellaver B, Leffa D, Lussier F, Povala G, Therriault J, Benedet AL, Ashton NJ, Cohen AD, Lopez OL, Tudorascu D, Klunk WE, Soucy JP, et al. Potential Utility of Plasma P-Tau and Neurofilament Light Chain as Surrogate Biomarkers for Preventive Clinical Trials. Neurology. PMID 36878697 DOI: 10.1212/WNL.0000000000207115 |
0.33 |
|
| 2023 |
De Bastiani MA, Bellaver B, Brum WS, Souza DG, Ferreira PCL, Rocha AS, Povala G, Ferrari-Souza JP, Benedet AL, Ashton NJ, Karikari TK, Zetterberg H, Blennow K, Rosa-Neto P, Pascoal TA, et al. Hippocampal GFAP-positive astrocyte responses to amyloid and tau pathologies. Brain, Behavior, and Immunity. 110: 175-184. PMID 36878332 DOI: 10.1016/j.bbi.2023.03.001 |
0.494 |
|
| 2023 |
Ashton NJ, Moseby-Knappe M, Benedet AL, Grötschel L, Lantero-Rodriguez J, Karikari TK, Hassager C, Wise MP, Stammet P, Kjaergaard J, Friberg H, Nielsen N, Cronberg T, Zetterberg H, Blennow K. Alzheimer Disease Blood Biomarkers in Patients With Out-of-Hospital Cardiac Arrest. Jama Neurology. PMID 36877496 DOI: 10.1001/jamaneurol.2023.0050 |
0.472 |
|
| 2023 |
Pascoal T, Bellaver B, Povala G, Ferreira P, Ferrari-Souza JP, Leffa D, Lussier F, Benedet A, Ashton N, Triana-Baltzerz G, Kolbzh H, Tissot C, Therriault J, Servaes S, Stevenson J, et al. Astrocyte reactivity influences the association of amyloid-β and tau biomarkers in preclinical Alzheimer's disease. Research Square. PMID 36778243 DOI: 10.21203/rs.3.rs-2507179/v1 |
0.542 |
|
| 2023 |
Mattsson-Carlgren N, Salvadó G, Ashton NJ, Tideman P, Stomrud E, Zetterberg H, Ossenkoppele R, Betthauser TJ, Cody KA, Jonaitis EM, Langhough R, Palmqvist S, Blennow K, Janelidze S, Johnson SC, et al. Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers. Jama Neurology. PMID 36745413 DOI: 10.1001/jamaneurol.2022.5272 |
0.513 |
|
| 2023 |
Bilgel M, An Y, Walker KA, Moghekar AR, Ashton NJ, Kac PR, Karikari TK, Blennow K, Zetterberg H, Jedynak BM, Thambisetty M, Ferrucci L, Resnick SM. Longitudinal changes in Alzheimer's-related plasma biomarkers and brain amyloid. Medrxiv : the Preprint Server For Health Sciences. PMID 36711545 DOI: 10.1101/2023.01.12.23284439 |
0.53 |
|
| 2023 |
Meng Y, Goubran M, Rabin JS, McSweeney M, Ottoy J, Pople CB, Huang Y, Storace A, Ozzoude M, Bethune A, Lam B, Swardfager W, Heyn C, Abrahao A, Davidson B, ... ... Ashton NJ, et al. Blood-brain barrier opening of the default mode network in Alzheimer's disease with magnetic resonance-guided focused ultrasound. Brain : a Journal of Neurology. PMID 36694943 DOI: 10.1093/brain/awac459 |
0.453 |
|
| 2022 |
Therriault J, Pascoal TA, Lussier FZ, Tissot C, Chamoun M, Bezgin G, Servaes S, Benedet AL, Ashton NJ, Karikari TK, Lantero-Rodriguez J, Kunach P, Wang YT, Fernandez-Arias J, Massarweh G, et al. Biomarker modeling of Alzheimer's disease using PET-based Braak staging. Nature Aging. 2: 526-535. PMID 37118445 DOI: 10.1038/s43587-022-00204-0 |
0.424 |
|
| 2022 |
Gonzalez-Ortiz F, Turton M, Kac PR, Smirnov D, Premi E, Ghidoni R, Benussi L, Cantoni V, Saraceno C, Rivolta J, Ashton NJ, Borroni B, Galasko D, Harrison P, Zetterberg H, et al. Brain-derived tau: a novel blood-based biomarker for Alzheimer's disease-type neurodegeneration. Brain : a Journal of Neurology. PMID 36572122 DOI: 10.1093/brain/awac407 |
0.518 |
|
| 2022 |
Simrén J, Brum WS, Ashton NJ, Benedet AL, Karikari TK, Kvartsberg H, Sjons E, Lussier FZ, Chamoun M, Stevenson J, Hopewell R, Pallen V, Ye K, Pascoal TA, Zetterberg H, et al. CSF tau368/total-tau ratio reflects cognitive performance and neocortical tau better compared to p-tau181 and p-tau217 in cognitively impaired individuals. Alzheimer's Research & Therapy. 14: 192. PMID 36544221 DOI: 10.1186/s13195-022-01142-0 |
0.448 |
|
| 2022 |
Gobom J, Benedet AL, Mattsson-Carlgren N, Montoliu-Gaya L, Schultz N, Ashton NJ, Janelidze S, Servaes S, Sauer M, Pascoal TA, Karikari TK, Lantero-Rodriguez J, Brinkmalm G, Zetterberg H, Hansson O, et al. Antibody-free measurement of cerebrospinal fluid tau phosphorylation across the Alzheimer's disease continuum. Molecular Neurodegeneration. 17: 81. PMID 36510321 DOI: 10.1186/s13024-022-00586-0 |
0.389 |
|
| 2022 |
Therriault J, Vermeiren M, Servaes S, Tissot C, Ashton NJ, Benedet AL, Karikari TK, Lantero-Rodriguez J, Brum WS, Lussier FZ, Bezgin G, Stevenson J, Rahmouni N, Kunach P, Wang YT, et al. Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography. Jama Neurology. PMID 36508198 DOI: 10.1001/jamaneurol.2022.4485 |
0.451 |
|
| 2022 |
Ashton NJ, Janelidze S, Mattsson-Carlgren N, Binette AP, Strandberg O, Brum WS, Karikari TK, González-Ortiz F, Di Molfetta G, Meda FJ, Jonaitis EM, Koscik RL, Cody K, Betthauser TJ, Li Y, et al. Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer's trial selection and disease monitoring. Nature Medicine. PMID 36456833 DOI: 10.1038/s41591-022-02074-w |
0.578 |
|
| 2022 |
Ferreira PCL, Bellaver B, Povala G, Brum WS, Tissot C, Badji A, Sloan ME, Benedet AL, Rosa-Neto P, Ashton NJ, Pascoal TA, Leuzy A, Zimmer ER. Endocannabinoid System Biomarkers in Alzheimer's Disease. Cannabis and Cannabinoid Research. PMID 36394442 DOI: 10.1089/can.2022.0151 |
0.538 |
|
| 2022 |
Benussi A, Cantoni V, Rivolta J, Archetti S, Micheli A, Ashton N, Zetterberg H, Blennow K, Borroni B. Classification accuracy of blood-based and neurophysiological markers in the differential diagnosis of Alzheimer's disease and frontotemporal lobar degeneration. Alzheimer's Research & Therapy. 14: 155. PMID 36229847 DOI: 10.1186/s13195-022-01094-5 |
0.523 |
|
| 2022 |
Depypere H, Vergallo A, Lemercier P, Lista S, Benedet A, Ashton N, Cavedo E, Zetterberg H, Blennow K, Vanmechelen E, Hampel H. Menopause hormone therapy significantly alters pathophysiological biomarkers of Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 36218064 DOI: 10.1002/alz.12759 |
0.44 |
|
| 2022 |
Öhrfelt A, Benedet AL, Ashton NJ, Kvartsberg H, Vandijck M, Weiner MW, Trojanowski JQ, Shaw LM, Zetterberg H, Blennow K. Association of CSF GAP-43 With the Rate of Cognitive Decline and Progression to Dementia in Amyloid-Positive Individuals. Neurology. PMID 36192174 DOI: 10.1212/WNL.0000000000201417 |
0.501 |
|
| 2022 |
Milà-Alomà M, Ashton NJ, Shekari M, Salvadó G, Ortiz-Romero P, Montoliu-Gaya L, Benedet AL, Karikari TK, Lantero-Rodriguez J, Vanmechelen E, Day TA, González-Escalante A, Sánchez-Benavides G, Minguillon C, Fauria K, et al. Publisher Correction: Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer's disease. Nature Medicine. 28: 1965. PMID 36100683 DOI: 10.1038/s41591-022-02037-1 |
0.462 |
|
| 2022 |
Janelidze S, Bali D, Ashton NJ, Barthélemy NR, Vanbrabant J, Stoops E, Vanmechelen E, He Y, Dolado AO, Triana-Baltzer G, Pontecorvo MJ, Zetterberg H, Kolb H, Vandijck M, Blennow K, et al. Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer's disease. Brain : a Journal of Neurology. PMID 36087307 DOI: 10.1093/brain/awac333 |
0.421 |
|
| 2022 |
Milà-Alomà M, Ashton NJ, Shekari M, Salvadó G, Ortiz-Romero P, Montoliu-Gaya L, Benedet AL, Karikari TK, Lantero-Rodriguez J, Vanmechelen E, Day TA, González-Escalante A, Sánchez-Benavides G, Minguillon C, Fauria K, et al. Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer's disease. Nature Medicine. PMID 35953717 DOI: 10.1038/s41591-022-01925-w |
0.548 |
|
| 2022 |
Ferrari-Souza JP, Ferreira PCL, Bellaver B, Tissot C, Wang YT, Leffa DT, Brum WS, Benedet AL, Ashton NJ, De Bastiani MA, Rocha A, Therriault J, Lussier FZ, Chamoun M, Servaes S, et al. Astrocyte biomarker signatures of amyloid-β and tau pathologies in Alzheimer's disease. Molecular Psychiatry. PMID 35948658 DOI: 10.1038/s41380-022-01716-2 |
0.525 |
|
| 2022 |
O'Connor A, Abel E, Benedet AL, Poole T, Ashton N, Weston PSJ, Heslegrave AJ, Ryan N, Barker S, Polke JM, Blennow K, Zetterberg H, Fox NC. Plasma GFAP in presymptomatic and symptomatic familial Alzheimer's disease: a longitudinal cohort study. Journal of Neurology, Neurosurgery, and Psychiatry. PMID 35948396 DOI: 10.1136/jnnp-2022-329663 |
0.425 |
|
| 2022 |
Benussi A, Libri I, Premi E, Alberici A, Cantoni V, Gadola Y, Rivolta J, Pengo M, Gazzina S, Calhoun VD, Gasparotti R, Zetterberg H, Ashton NJ, Blennow K, Padovani A, et al. Differences and similarities between familial and sporadic frontotemporal dementia: An Italian single-center cohort study. Alzheimer's & Dementia (New York, N. Y.). 8: e12326. PMID 35898667 DOI: 10.1002/trc2.12326 |
0.319 |
|
| 2022 |
Michalowska MM, Herholz K, Hinz R, Amadi C, McInnes L, Anton-Rodriguez JM, Karikari TK, Blennow K, Zetterberg H, Ashton NJ, Pendleton N, Carter SF. Evaluation of in vivo staging of amyloid deposition in cognitively unimpaired elderly aged 78-94. Molecular Psychiatry. PMID 35858992 DOI: 10.1038/s41380-022-01685-6 |
0.342 |
|
| 2022 |
Salvadó G, Milà-Alomà M, Shekari M, Ashton NJ, Operto G, Falcon C, Cacciaglia R, Minguillon C, Fauria K, Niñerola-Baizán A, Perissinotti A, Benedet AL, Kollmorgen G, Suridjan I, Wild N, et al. Reactive astrogliosis is associated with higher cerebral glucose consumption in the early Alzheimer's continuum. European Journal of Nuclear Medicine and Molecular Imaging. PMID 35849149 DOI: 10.1007/s00259-022-05897-4 |
0.437 |
|
| 2022 |
Karikari TK, Ashton NJ, Zetterberg H, Blennow K. Editorial: Blood Biomarkers of Neurodegenerative Diseases. Frontiers in Molecular Neuroscience. 15: 966139. PMID 35845608 DOI: 10.3389/fnmol.2022.966139 |
0.332 |
|
| 2022 |
Nilsson J, Ashton NJ, Benedet AL, Montoliu-Gaya L, Gobom J, Pascoal TA, Chamoun M, Portelius E, Jeromin A, Mendes M, Zetterberg H, Rosa-Neto P, Brinkmalm A, Blennow K. Quantification of SNAP-25 with mass spectrometry and Simoa: a method comparison in Alzheimer's disease. Alzheimer's Research & Therapy. 14: 78. PMID 35659284 DOI: 10.1186/s13195-022-01021-8 |
0.527 |
|
| 2022 |
Shahim P, Zetterberg H, Simren J, Ashton NJ, Norato G, Schöll M, Tegner Y, Diaz-Arrastia R, Blennow K. Association of Plasma Biomarker Levels With Their CSF Concentration and the Number and Severity of Concussions in Professional Athletes. Neurology. PMID 35654597 DOI: 10.1212/WNL.0000000000200615 |
0.429 |
|
| 2022 |
Karikari TK, Ashton NJ, Brinkmalm G, Brum WS, Benedet AL, Montoliu-Gaya L, Lantero-Rodriguez J, Pascoal TA, Suárez-Calvet M, Rosa-Neto P, Blennow K, Zetterberg H. Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility. Nature Reviews. Neurology. PMID 35585226 DOI: 10.1038/s41582-022-00665-2 |
0.473 |
|
| 2022 |
Morrison MS, Aparicio HJ, Blennow K, Zetterberg H, Ashton NJ, Karikari TK, Tripodis Y, Martin B, Palmisano JN, Sugarman MA, Frank B, Steinberg EG, Turk KW, Budson AE, Au R, et al. Antemortem plasma phosphorylated tau (181) predicts Alzheimer's disease neuropathology and regional tau at autopsy. Brain : a Journal of Neurology. PMID 35554506 DOI: 10.1093/brain/awac175 |
0.541 |
|
| 2022 |
Kac PR, Gonzalez-Ortiz F, Simrén J, Dewit N, Vanmechelen E, Zetterberg H, Blennow K, Ashton NJ, Karikari TK. Diagnostic value of serum versus plasma phospho-tau for Alzheimer's disease. Alzheimer's Research & Therapy. 14: 65. PMID 35545792 DOI: 10.1186/s13195-022-01011-w |
0.542 |
|
| 2022 |
Gerards M, Schild AK, Meiberth D, Rostamzadeh A, Vehreschild JJ, Wingen-Heimann S, Johannis W, Martino Adami P, Onur OA, Ramirez A, Karikari TK, Ashton NJ, Zetterberg H, Blennow K, Maier F, et al. Alzheimer's Disease Plasma Biomarkers Distinguish Clinical Diagnostic Groups in Memory Clinic Patients. Dementia and Geriatric Cognitive Disorders. 1-11. PMID 35504263 DOI: 10.1159/000524390 |
0.443 |
|
| 2022 |
Smailovic U, Ferreira D, Ausén B, Ashton NJ, Koenig T, Zetterberg H, Blennow K, Jelic V. Decreased Electroencephalography Global Field Synchronization in Slow-Frequency Bands Characterizes Synaptic Dysfunction in Amnestic Subtypes of Mild Cognitive Impairment. Frontiers in Aging Neuroscience. 14: 755454. PMID 35462693 DOI: 10.3389/fnagi.2022.755454 |
0.383 |
|
| 2022 |
Schindler SE, Karikari TK, Ashton NJ, Henson RL, Yarasheski KE, West T, Meyer MR, Kirmess KM, Li Y, Saef B, Moulder KL, Bradford D, Fagan AM, Gordon BA, Benzinger TLS, et al. Effect of Race on Prediction of Brain Amyloidosis by Plasma Aβ42/Aβ40, Phosphorylated Tau, and Neurofilament Light. Neurology. PMID 35450967 DOI: 10.1212/WNL.0000000000200358 |
0.446 |
|
| 2022 |
Pilotto A, Parigi M, Bonzi G, Battaglio B, Ferrari E, Mensi L, Benussi A, Caratozzolo S, Cosseddu M, Turrone R, Archetti S, Ashton NJ, Zetterberg H, Giliani S, Padovani A. Differences Between Plasma and Cerebrospinal Fluid p-tau181 and p-tau231 in Early Alzheimer's Disease. Journal of Alzheimer's Disease : Jad. PMID 35404280 DOI: 10.3233/JAD-215646 |
0.516 |
|
| 2022 |
Snellman A, Lantero-Rodriguez J, Emeršič A, Vrillon A, Karikari TK, Ashton NJ, Gregorič Kramberger M, Čučnik S, Paquet C, Rot U, Zetterberg H, Blennow K. N-terminal and mid-region tau fragments as fluid biomarkers in neurological diseases. Brain : a Journal of Neurology. PMID 35311972 DOI: 10.1093/brain/awab481 |
0.425 |
|
| 2022 |
Brum WS, de Bastiani MA, Bieger A, Therriault J, Ferrari-Souza JP, Benedet AL, Saha-Chaudhuri P, Souza DO, Ashton NJ, Zetterberg H, Pascoal TA, Karikari T, Blennow K, Rosa-Neto P, Zimmer ER. A three-range approach enhances the prognostic utility of CSF biomarkers in Alzheimer's disease. Alzheimer's & Dementia (New York, N. Y.). 8: e12270. PMID 35310530 DOI: 10.1002/trc2.12270 |
0.436 |
|
| 2022 |
Imarisio A, Pilotto A, Garrafa E, Conforti F, Masciocchi S, Turrone R, Gipponi S, Cottini E, Rizzetti MC, Porrini V, Gussago C, Pizzi M, Guadagni F, Zetterberg H, Ashton NJ, et al. Plasma Cystatin C correlates with plasma NfL levels and predicts disease progression in Parkinson's disease. Neuro-Degenerative Diseases. PMID 35287127 DOI: 10.1159/000523982 |
0.312 |
|
| 2022 |
Dittrich A, Ashton NJ, Zetterberg H, Blennow K, Simrén J, Geiger F, Zettergren A, Shams S, Machado A, Westman E, Schöll M, Skoog I, Kern S. Plasma and CSF NfL are differentially associated with biomarker evidence of neurodegeneration in a community-based sample of 70-year-olds. Alzheimer's & Dementia (Amsterdam, Netherlands). 14: e12295. PMID 35280965 DOI: 10.1002/dad2.12295 |
0.482 |
|
| 2022 |
Moscoso A, Karikari TK, Grothe MJ, Ashton NJ, Lantero-Rodriguez J, Snellman A, Zetterberg H, Blennow K, Schöll M. CSF biomarkers and plasma p-tau181 as predictors of longitudinal tau accumulation: Implications for clinical trial design. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 35226405 DOI: 10.1002/alz.12570 |
0.489 |
|
| 2022 |
Smirnov DS, Ashton NJ, Blennow K, Zetterberg H, Simrén J, Lantero-Rodriguez J, Karikari TK, Hiniker A, Rissman RA, Salmon DP, Galasko D. Plasma biomarkers for Alzheimer's Disease in relation to neuropathology and cognitive change. Acta Neuropathologica. PMID 35195758 DOI: 10.1007/s00401-022-02408-5 |
0.586 |
|
| 2022 |
Ashton NJ, Benedet AL, Pascoal TA, Karikari TK, Lantero-Rodriguez J, Brum WS, Mathotaarachchi S, Therriault J, Savard M, Chamoun M, Stoops E, Francois C, Vanmechelen E, Gauthier S, Zimmer ER, et al. Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease. Ebiomedicine. 76: 103836. PMID 35158308 DOI: 10.1016/j.ebiom.2022.103836 |
0.508 |
|
| 2022 |
Tissot C, Therriault J, Kunach P, L Benedet A, Pascoal TA, Ashton NJ, Karikari TK, Servaes S, Lussier FZ, Chamoun M, Tudorascu DL, Stevenson J, Rahmouni N, Poltronetti NM, Pallen V, et al. Comparing tau status determined via plasma pTau181, pTau231 and [F]MK6240 tau-PET. Ebiomedicine. 76: 103837. PMID 35134647 DOI: 10.1016/j.ebiom.2022.103837 |
0.412 |
|
| 2022 |
Benedet AL, Brum WS, Hansson O, Karikari TK, Zimmer ER, Zetterberg H, Blennow K, Ashton NJ. The accuracy and robustness of plasma biomarker models for amyloid PET positivity. Alzheimer's Research & Therapy. 14: 26. PMID 35130933 DOI: 10.1186/s13195-021-00942-0 |
0.544 |
|
| 2022 |
Padovani A, Canale A, Schiavon L, Masciocchi S, Imarisio A, Risi B, Bonzi G, De Giuli V, Di Luca M, Ashton NJ, Blennow K, Zetterberg H, Pilotto A. Is amyloid involved in acute neuroinflammation? A CSF analysis in encephalitis. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 35084105 DOI: 10.1002/alz.12554 |
0.341 |
|
| 2022 |
Meyer PF, Ashton NJ, Karikari TK, Strikwerda-Brown C, Köbe T, Gonneaud J, Pichet Binette A, Ozlen H, Yakoub Y, Simrén J, Pannee J, Lantero-Rodriguez J, Labonté A, Baker SL, Schöll M, et al. Plasma p-tau231, p-tau181, PET biomarkers and cognitive change in older adults. Annals of Neurology. PMID 35084051 DOI: 10.1002/ana.26308 |
0.393 |
|
| 2022 |
Pereira JB, Janelidze S, Smith R, Mattsson-Carlgren N, Palmqvist S, Teunissen CE, Zetterberg H, Stomrud E, Ashton NJ, Blennow K, Hansson O. Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer's disease. Brain : a Journal of Neurology. 144: 3505-3516. PMID 34259835 DOI: 10.1093/brain/awab223 |
0.443 |
|
| 2021 |
Bayoumy S, Verberk IMW, den Dulk B, Hussainali Z, Zwan M, van der Flier WM, Ashton NJ, Zetterberg H, Blennow K, Vanbrabant J, Stoops E, Vanmechelen E, Dage JL, Teunissen CE. Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231. Alzheimer's Research & Therapy. 13: 198. PMID 34863295 DOI: 10.1186/s13195-021-00939-9 |
0.359 |
|
| 2021 |
Frank B, Ally M, Brekke B, Zetterberg H, Blennow K, Sugarman MA, Ashton NJ, Karikari TK, Tripodis Y, Martin B, Palmisano JN, Steinberg EG, Simkina I, Turk KW, Budson AE, et al. Plasma p-tau shows stronger network association to Alzheimer's disease dementia than neurofilament light and total tau. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 34854549 DOI: 10.1002/alz.12508 |
0.53 |
|
| 2021 |
Gonzalez MC, Ashton NJ, Gomes BF, Tovar-Rios DA, Blanc F, Karikari TK, Mollenhauer B, Pilotto A, Lemstra A, Paquet C, Abdelnour C, Kramberger MG, Bonanni L, Vandenberghe R, Hye A, et al. Association of Plasma p-tau181 and p-tau231 Concentrations With Cognitive Decline in Patients With Probable Dementia With Lewy Bodies. Jama Neurology. PMID 34807233 DOI: 10.1001/jamaneurol.2021.4222 |
0.53 |
|
| 2021 |
Benussi A, Ashton NJ, Karikari TK, Alberici A, Saraceno C, Ghidoni R, Benussi L, Zetterberg H, Blennow K, Borroni B. Prodromal frontotemporal dementia: clinical features and predictors of progression. Alzheimer's Research & Therapy. 13: 188. PMID 34782010 DOI: 10.1186/s13195-021-00932-2 |
0.326 |
|
| 2021 |
Gobom J, Parnetti L, Rosa-Neto P, Vyhnalek M, Gauthier S, Cataldi S, Lerch O, Laczo J, Cechova K, Clarin M, Benet AI, Pascoal TA, Rahmouni N, Vandijck M, Huyck E, ... ... Ashton N, et al. Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid. Clinical Chemistry and Laboratory Medicine. PMID 34773730 DOI: 10.1515/cclm-2021-0651 |
0.518 |
|
| 2021 |
Lantero-Rodriguez J, Snellman A, Benedet AL, Milà-Alomà M, Camporesi E, Montoliu-Gaya L, Ashton NJ, Vrillon A, Karikari TK, Gispert JD, Salvadó G, Shekari M, Toomey CE, Lashley TL, Zetterberg H, et al. P-tau235: a novel biomarker for staging preclinical Alzheimer's disease. Embo Molecular Medicine. e15098. PMID 34725927 DOI: 10.15252/emmm.202115098 |
0.492 |
|
| 2021 |
Benedet AL, Milà-Alomà M, Vrillon A, Ashton NJ, Pascoal TA, Lussier F, Karikari TK, Hourregue C, Cognat E, Dumurgier J, Stevenson J, Rahmouni N, Pallen V, Poltronetti NM, Salvadó G, et al. Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum. Jama Neurology. PMID 34661615 DOI: 10.1001/jamaneurol.2021.3671 |
0.499 |
|
| 2021 |
Picard C, Nilsson N, Labonté A, Auld D, Rosa-Neto P, Ashton NJ, Zetterberg H, Blennow K, Breitner JCB, Villeneuve S, Poirier J. Apolipoprotein B is a novel marker for early tau pathology in Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 34590423 DOI: 10.1002/alz.12442 |
0.425 |
|
| 2021 |
Milà-Alomà M, Brinkmalm A, Ashton NJ, Kvartsberg H, Shekari M, Operto G, Salvadó G, Falcon C, Gispert JD, Vilor-Tejedor N, Arenaza-Urquijo EM, Grau-Rivera O, Sala-Vila A, Sanchez-Benavides G, González-de-Echávarri JM, et al. CSF Synaptic Biomarkers in the Preclinical Stage of Alzheimer Disease and Their Association With MRI and PET: A Cross-sectional Study. Neurology. 97: e2065-e2078. PMID 34556565 DOI: 10.1212/WNL.0000000000012853 |
0.47 |
|
| 2021 |
Boccardi M, Dodich A, Albanese E, Gayet-Ageron A, Festari C, Ashton NJ, Bischof GN, Chiotis K, Leuzy A, Wolters EE, Walter M, Rabinovici GD, Carrillo M, Drzezga A, Hansson O, et al. Correction to: The Strategic Biomarker Roadmap for the validation of Alzheimer's diagnostic biomarkers: methodological update. European Journal of Nuclear Medicine and Molecular Imaging. PMID 34546388 DOI: 10.1007/s00259-021-05549-z |
0.415 |
|
| 2021 |
Chong JR, Ashton NJ, Karikari TK, Tanaka T, Schöll M, Zetterberg H, Blennow K, Chen CP, Lai MKP. Blood-based high sensitivity measurements of beta-amyloid and phosphorylated tau as biomarkers of Alzheimer's disease: a focused review on recent advances. Journal of Neurology, Neurosurgery, and Psychiatry. PMID 34510001 DOI: 10.1136/jnnp-2021-327370 |
0.543 |
|
| 2021 |
Chatterjee P, Pedrini S, Ashton NJ, Tegg M, Goozee K, Singh AK, Karikari TK, Simrén J, Vanmechelen E, Armstrong NJ, Hone E, Asih PR, Taddei K, Doré V, Villemagne VL, et al. Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 34494715 DOI: 10.1002/alz.12447 |
0.549 |
|
| 2021 |
Pascoal TA, Benedet AL, Ashton NJ, Kang MS, Therriault J, Chamoun M, Savard M, Lussier FZ, Tissot C, Karikari TK, Ottoy J, Mathotaarachchi S, Stevenson J, Massarweh G, Schöll M, et al. Microglial activation and tau propagate jointly across Braak stages. Nature Medicine. PMID 34446931 DOI: 10.1038/s41591-021-01456-w |
0.45 |
|
| 2021 |
Montoliu-Gaya L, Strydom A, Blennow K, Zetterberg H, Ashton NJ. Blood Biomarkers for Alzheimer's Disease in Down Syndrome. Journal of Clinical Medicine. 10. PMID 34441934 DOI: 10.3390/jcm10163639 |
0.538 |
|
| 2021 |
Smailovic U, Kåreholt I, Koenig T, Ashton NJ, Winblad B, Höglund K, Nilsson P, Zetterberg H, Blennow K, Jelic V. Synaptic Molecular and Neurophysiological Markers Are Independent Predictors of Progression in Alzheimer's Disease. Journal of Alzheimer's Disease : Jad. PMID 34334389 DOI: 10.3233/JAD-201234 |
0.437 |
|
| 2021 |
Mielke MM, Frank RD, Dage JL, Jeromin A, Ashton NJ, Blennow K, Karikari TK, Vanmechelen E, Zetterberg H, Algeciras-Schimnich A, Knopman DS, Lowe V, Bu G, Vemuri P, Graff-Radford J, et al. Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes. Jama Neurology. PMID 34309632 DOI: 10.1001/jamaneurol.2021.2293 |
0.351 |
|
| 2021 |
Grothe MJ, Moscoso A, Ashton NJ, Karikari TK, Lantero-Rodriguez J, Snellman A, Zetterberg H, Blennow K, Schöll M. Associations of Fully Automated CSF and Novel Plasma Biomarkers With Alzheimer Disease Neuropathology at Autopsy. Neurology. PMID 34266917 DOI: 10.1212/WNL.0000000000012513 |
0.582 |
|
| 2021 |
Lleó A, Zetterberg H, Pegueroles J, Karikari TK, Carmona-Iragui M, Ashton NJ, Montal V, Barroeta I, Lantero-Rodríguez J, Videla L, Altuna M, Benejam B, Fernandez S, Valldeneu S, Garzón D, et al. Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer's disease in adults with Down syndrome. Nature Communications. 12: 4304. PMID 34262030 DOI: 10.1038/s41467-021-24319-x |
0.549 |
|
| 2021 |
Therriault J, Benedet AL, Pascoal TA, Lussier FZ, Tissot C, Karikari TK, Ashton NJ, Chamoun M, Bezgin G, Mathotaarachchi S, Gauthier S, Saha-Chaudhuri P, Zetterberg H, Blennow K, Rosa-Neto P, et al. Association of plasma P-tau181 with memory decline in non-demented adults. Brain Communications. 3: fcab136. PMID 34222875 DOI: 10.1093/braincomms/fcab136 |
0.47 |
|
| 2021 |
Pilotto A, Imarisio A, Carrarini C, Russo M, Masciocchi S, Gipponi S, Cottini E, Aarsland D, Zetterberg H, Ashton NJ, Hye A, Bonanni L, Padovani A. Plasma Neurofilament Light Chain Predicts Cognitive Progression in Prodromal and Clinical Dementia with Lewy Bodies. Journal of Alzheimer's Disease : Jad. 82: 913-919. PMID 34151807 DOI: 10.3233/JAD-210342 |
0.382 |
|
| 2021 |
Janelidze S, Palmqvist S, Leuzy A, Stomrud E, Verberk IMW, Zetterberg H, Ashton NJ, Pesini P, Sarasa L, Allué JA, Teunissen CE, Dage JL, Blennow K, Mattsson-Carlgren N, Hansson O. Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p-tau. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 34151519 DOI: 10.1002/alz.12395 |
0.54 |
|
| 2021 |
Ashton NJ, Blennow K, Zetterberg H. Spitting image: can saliva biomarkers reflect Alzheimer's disease? Ebiomedicine. 68: 103437. PMID 34134088 DOI: 10.1016/j.ebiom.2021.103437 |
0.411 |
|
| 2021 |
Ashton NJ, Suárez-Calvet M, Karikari TK, Lantero-Rodriguez J, Snellman A, Sauer M, Simrén J, Minguillon C, Fauria K, Blennow K, Zetterberg H. Effects of pre-analytical procedures on blood biomarkers for Alzheimer's pathophysiology, glial activation, and neurodegeneration. Alzheimer's & Dementia (Amsterdam, Netherlands). 13: e12168. PMID 34124336 DOI: 10.1002/dad2.12168 |
0.424 |
|
| 2021 |
Lord J, Zettergren A, Ashton NJ, Karikari TK, Benedet AL, Simrén J, Hye A, Aarsland D, Blennow K, Zetterberg H, Proitsi P. A genome-wide association study of plasma phosphorylated tau181. Neurobiology of Aging. 106: 304.e1-304.e3. PMID 34119372 DOI: 10.1016/j.neurobiolaging.2021.04.018 |
0.384 |
|
| 2021 |
Alcolea D, Delaby C, Muñoz L, Torres S, Estellés T, Zhu N, Barroeta I, Carmona-Iragui M, Illán-Gala I, Santos-Santos MÁ, Altuna M, Sala I, Sánchez-Saudinós MB, Videla L, Valldeneu S, ... ... Ashton NJ, et al. Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias. Journal of Neurology, Neurosurgery, and Psychiatry. PMID 34103344 DOI: 10.1136/jnnp-2021-326603 |
0.454 |
|
| 2021 |
Ashton NJ, Janelidze S, Al Khleifat A, Leuzy A, van der Ende EL, Karikari TK, Benedet AL, Pascoal TA, Lleó A, Parnetti L, Galimberti D, Bonanni L, Pilotto A, Padovani A, Lycke J, et al. A multicentre validation study of the diagnostic value of plasma neurofilament light. Nature Communications. 12: 3400. PMID 34099648 DOI: 10.1038/s41467-021-23620-z |
0.331 |
|
| 2021 |
Gleerup HS, Sanna F, Høgh P, Simrén J, Blennow K, Zetterberg H, Hasselbalch SG, Ashton NJ, Simonsen AH. Saliva Neurofilament Light Chain Is Not a Diagnostic Biomarker for Neurodegeneration in a Mixed Memory Clinic Population. Frontiers in Aging Neuroscience. 13: 659898. PMID 34040512 DOI: 10.3389/fnagi.2021.659898 |
0.553 |
|
| 2021 |
Nilsson J, Gobom J, Sjödin S, Brinkmalm G, Ashton NJ, Svensson J, Johansson P, Portelius E, Zetterberg H, Blennow K, Brinkmalm A. Cerebrospinal fluid biomarker panel for synaptic dysfunction in Alzheimer's disease. Alzheimer's & Dementia (Amsterdam, Netherlands). 13: e12179. PMID 33969172 DOI: 10.1002/dad2.12179 |
0.458 |
|
| 2021 |
Lussier FZ, Benedet AL, Therriault J, Pascoal TA, Tissot C, Chamoun M, Mathotaarachchi S, Savard M, Ashton NJ, Karikari TK, Rodriguez JL, Snellman A, Bezgin G, Kang MS, Fernandez Arias J, et al. Plasma levels of phosphorylated tau 181 are associated with cerebral metabolic dysfunction in cognitively impaired and amyloid-positive individuals. Brain Communications. 3: fcab073. PMID 33959711 DOI: 10.1093/braincomms/fcab073 |
0.492 |
|
| 2021 |
Chong JR, Ashton NJ, Karikari TK, Tanaka T, Saridin FN, Reilhac A, Robins EG, Nai YH, Vrooman H, Hilal S, Zetterberg H, Blennow K, Lai MKP, Chen CP. Plasma P-tau181 to Aβ42 ratio is associated with brain amyloid burden and hippocampal atrophy in an Asian cohort of Alzheimer's disease patients with concomitant cerebrovascular disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 33792168 DOI: 10.1002/alz.12332 |
0.55 |
|
| 2021 |
Shi L, Winchester LM, Westwood S, Baird AL, Anand SN, Buckley NJ, Hye A, Ashton NJ, Bos I, Vos SJB, Kate MT, Scheltens P, Teunissen CE, Vandenberghe R, Gabel S, et al. Replication study of plasma proteins relating to Alzheimer's pathology. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 33792144 DOI: 10.1002/alz.12322 |
0.673 |
|
| 2021 |
Tissot C, L Benedet A, Therriault J, Pascoal TA, Lussier FZ, Saha-Chaudhuri P, Chamoun M, Savard M, Mathotaarachchi SS, Bezgin G, Wang YT, Fernandez Arias J, Rodriguez JL, Snellman A, Ashton NJ, et al. Plasma pTau181 predicts cortical brain atrophy in aging and Alzheimer's disease. Alzheimer's Research & Therapy. 13: 69. PMID 33781319 DOI: 10.1186/s13195-021-00802-x |
0.422 |
|
| 2021 |
Boccardi M, Dodich A, Albanese E, Gayet-Ageron A, Festari C, Ashton NJ, Bischof GN, Chiotis K, Leuzy A, Wolters EE, Walter MA, Rabinovici GD, Carrillo M, Drzezga A, Hansson O, et al. The strategic biomarker roadmap for the validation of Alzheimer's diagnostic biomarkers: methodological update. European Journal of Nuclear Medicine and Molecular Imaging. PMID 33688996 DOI: 10.1007/s00259-020-05120-2 |
0.457 |
|
| 2021 |
Ashton NJ, Pascoal TA, Karikari TK, Benedet AL, Lantero-Rodriguez J, Brinkmalm G, Snellman A, Schöll M, Troakes C, Hye A, Gauthier S, Vanmechelen E, Zetterberg H, Rosa-Neto P, Blennow K. Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology. Acta Neuropathologica. PMID 33585983 DOI: 10.1007/s00401-021-02275-6 |
0.528 |
|
| 2021 |
Simrén J, Leuzy A, Karikari TK, Hye A, Benedet AL, Lantero-Rodriguez J, Mattsson-Carlgren N, Schöll M, Mecocci P, Vellas B, Tsolaki M, Kloszewska I, Soininen H, Lovestone S, Aarsland D, ... ... Ashton NJ, et al. The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 33491853 DOI: 10.1002/alz.12283 |
0.63 |
|
| 2021 |
Keshavan A, Pannee J, Karikari TK, Rodriguez JL, Ashton NJ, Nicholas JM, Cash DM, Coath W, Lane CA, Parker TD, Lu K, Buchanan SM, Keuss SE, James SN, Murray-Smith H, et al. Population-based blood screening for preclinical Alzheimer's disease in a British birth cohort at age 70. Brain : a Journal of Neurology. PMID 33479777 DOI: 10.1093/brain/awaa403 |
0.401 |
|
| 2021 |
Moscoso A, Grothe MJ, Ashton NJ, Karikari TK, Lantero Rodríguez J, Snellman A, Suárez-Calvet M, Blennow K, Zetterberg H, Schöll M. Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease. Jama Neurology. PMID 33427873 DOI: 10.1001/jamaneurol.2020.4986 |
0.55 |
|
| 2021 |
Zettergren A, Lord J, Ashton NJ, Benedet AL, Karikari TK, Lantero Rodriguez J, Snellman A, Suárez-Calvet M, Proitsi P, Zetterberg H, Blennow K. Association between polygenic risk score of Alzheimer's disease and plasma phosphorylated tau in individuals from the Alzheimer's Disease Neuroimaging Initiative. Alzheimer's Research & Therapy. 13: 17. PMID 33419453 DOI: 10.1186/s13195-020-00754-8 |
0.596 |
|
| 2020 |
Tanaka T, Ruifen JC, Ying-Hwey N, Tan CH, Lim CZJ, Zhang Y, Stephenson MC, Hilal S, Saridin FN, Gyanwali B, Villaraza S, Robins EG, Ihara M, Schöll M, Zetterberg H, ... ... Ashton NJ, et al. Head-to-head comparison of amplified plasmonic exosome Aβ42 platform and single-molecule array immunoassay in a memory clinic cohort. European Journal of Neurology. PMID 33370497 DOI: 10.1111/ene.14704 |
0.344 |
|
| 2020 |
Öhrfelt A, Dumurgier J, Zetterberg H, Vrillon A, Ashton NJ, Kvartsberg H, Bouaziz-Amar E, Hugon J, Paquet C, Blennow K. Full-length and C-terminal neurogranin in Alzheimer's disease cerebrospinal fluid analyzed by novel ultrasensitive immunoassays. Alzheimer's Research & Therapy. 12: 168. PMID 33353563 DOI: 10.1186/s13195-020-00748-6 |
0.48 |
|
| 2020 |
Millere E, Rots D, Simrén J, Ashton NJ, Kupats E, Micule I, Priedite V, Kurjane N, Blennow K, Gailite L, Zetterberg H, Kenina V. Plasma neurofilament light chain as a potential biomarker in Charcot-Marie-Tooth disease. European Journal of Neurology. PMID 33340200 DOI: 10.1111/ene.14689 |
0.306 |
|
| 2020 |
Kurbatova N, Garg M, Whiley L, Chekmeneva E, Jiménez B, Gómez-Romero M, Pearce J, Kimhofer T, D'Hondt E, Soininen H, Kłoszewska I, Mecocci P, Tsolaki M, Vellas B, Aarsland D, ... ... Ashton NJ, et al. Urinary metabolic phenotyping for Alzheimer's disease. Scientific Reports. 10: 21745. PMID 33303834 DOI: 10.1038/s41598-020-78031-9 |
0.566 |
|
| 2020 |
Moscoso A, Grothe MJ, Ashton NJ, Karikari TK, Rodriguez JL, Snellman A, Suárez-Calvet M, Zetterberg H, Blennow K, Schöll M. Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum. Brain : a Journal of Neurology. PMID 33257949 DOI: 10.1093/brain/awaa399 |
0.56 |
|
| 2020 |
Karikari TK, Emeršič A, Vrillon A, Lantero-Rodriguez J, Ashton NJ, Kramberger MG, Dumurgier J, Hourregue C, Čučnik S, Brinkmalm G, Rot U, Zetterberg H, Paquet C, Blennow K. Head-to-head comparison of clinical performance of CSF phospho-tau T181 and T217 biomarkers for Alzheimer's disease diagnosis. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 33252199 DOI: 10.1002/alz.12236 |
0.464 |
|
| 2020 |
Benedet AL, Leuzy A, Pascoal TA, Ashton NJ, Mathotaarachchi S, Savard M, Therriault J, Kang MS, Chamoun M, Schöll M, Zimmer ER, Gauthier S, Labbe A, Zetterberg H, Rosa-Neto P, et al. Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease. Brain : a Journal of Neurology. PMID 33210117 DOI: 10.1093/brain/awaa342 |
0.52 |
|
| 2020 |
Suárez-Calvet M, Karikari TK, Ashton NJ, Lantero Rodríguez J, Milà-Alomà M, Gispert JD, Salvadó G, Minguillon C, Fauria K, Shekari M, Grau-Rivera O, Arenaza-Urquijo EM, Sala-Vila A, Sánchez-Benavides G, González-de-Echávarri JM, et al. Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer's continuum when only subtle changes in Aβ pathology are detected. Embo Molecular Medicine. e12921. PMID 33169916 DOI: 10.15252/emmm.202012921 |
0.502 |
|
| 2020 |
Karikari TK, Benedet AL, Ashton NJ, Lantero Rodriguez J, Snellman A, Suárez-Calvet M, Saha-Chaudhuri P, Lussier F, Kvartsberg H, Rial AM, Pascoal TA, Andreasson U, Schöll M, Weiner MW, Rosa-Neto P, et al. Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative. Molecular Psychiatry. PMID 33106600 DOI: 10.1038/s41380-020-00923-z |
0.614 |
|
| 2020 |
Shi L, Winchester LM, Liu BY, Killick R, Ribe EM, Westwood S, Baird AL, Buckley NJ, Hong S, Dobricic V, Kilpert F, Franke A, Kiddle S, Sattlecker M, Dobson R, ... ... Ashton NJ, et al. Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer's Disease Pathology. Journal of Alzheimer's Disease : Jad. PMID 32831200 DOI: 10.3233/Jad-200208 |
0.607 |
|
| 2020 |
Therriault J, Benedet A, Pascoal TA, Savard M, Ashton N, Chamoun M, Tissot C, Lussier F, Kang MSP, Bergin G, Wang T, Fernandez-Arias J, Massarweh G, Tissot C, Zetterberg H, et al. Determining Amyloid-β positivity using [F]AZD4694 PET imaging. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 32737243 DOI: 10.2967/Jnumed.120.245209 |
0.342 |
|
| 2020 |
Lantero Rodriguez J, Karikari TK, Suárez-Calvet M, Troakes C, King A, Emersic A, Aarsland D, Hye A, Zetterberg H, Blennow K, Ashton NJ. Plasma p-tau181 accurately predicts Alzheimer's disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline. Acta Neuropathologica. 140: 267-278. PMID 32720099 DOI: 10.1007/s00401-020-02195-x |
0.571 |
|
| 2020 |
O'Connor A, Karikari TK, Poole T, Ashton NJ, Lantero Rodriguez J, Khatun A, Swift I, Heslegrave AJ, Abel E, Chung E, Weston PSJ, Pavisic IM, Ryan NS, Barker S, Rossor MN, et al. Plasma phospho-tau181 in presymptomatic and symptomatic familial Alzheimer's disease: a longitudinal cohort study. Molecular Psychiatry. PMID 32665603 DOI: 10.1038/S41380-020-0838-X |
0.444 |
|
| 2020 |
Chatterjee P, Mohammadi M, Goozee K, Shah TM, Sohrabi HR, Dias CB, Shen K, Asih PR, Dave P, Pedrini S, Ashton NJ, Hye A, Taddei K, Lovejoy DB, Zetterberg H, et al. Serum Hepcidin Levels in Cognitively Normal Older Adults with High Neocortical Amyloid-β Load. Journal of Alzheimer's Disease : Jad. PMID 32538848 DOI: 10.3233/JAD-200162 |
0.302 |
|
| 2020 |
Ashraf A, Ashton NJ, Chatterjee P, Goozee K, Shen K, Fripp J, Ames D, Rowe C, Masters CL, Villemagne V, Hye A, Martins RN, So PW. Plasma transferrin and hemopexin are associated with altered Aβ uptake and cognitive decline in Alzheimer's disease pathology. Alzheimer's Research & Therapy. 12: 72. PMID 32517787 DOI: 10.1186/S13195-020-00634-1 |
0.493 |
|
| 2020 |
Ehrenberg AJ, Khatun A, Coomans E, Betts MJ, Capraro F, Thijssen EH, Senkevich K, Bharucha T, Jafarpour M, Young PNE, Jagust W, Carter SF, Lashley T, Grinberg LT, Pereira JB, ... ... Ashton NJ, et al. Relevance of biomarkers across different neurodegenerative. Alzheimer's Research & Therapy. 12: 56. PMID 32404143 DOI: 10.1186/S13195-020-00601-W |
0.372 |
|
| 2020 |
Karikari TK, Pascoal TA, Ashton NJ, Janelidze S, Benedet AL, Rodriguez JL, Chamoun M, Savard M, Kang MS, Therriault J, Schöll M, Massarweh G, Soucy JP, Höglund K, Brinkmalm G, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. The Lancet. Neurology. 19: 422-433. PMID 32333900 DOI: 10.1016/S1474-4422(20)30071-5 |
0.544 |
|
| 2020 |
Ashton NJ, Hye A, Rajkumar AP, Leuzy A, Snowden S, Suárez-Calvet M, Karikari TK, Schöll M, La Joie R, Rabinovici GD, Höglund K, Ballard C, Hortobágyi T, Svenningsson P, Blennow K, et al. An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders. Nature Reviews. Neurology. 16: 265-284. PMID 32322100 DOI: 10.1038/S41582-020-0348-0 |
0.459 |
|
| 2020 |
Obrocki P, Khatun A, Ness D, Senkevich K, Hanrieder J, Capraro F, Mattsson N, Andreasson U, Portelius E, Ashton NJ, Blennow K, Schöll M, Paterson RW, Schott JM, Zetterberg H. Perspectives in fluid biomarkers in neurodegeneration from the 2019 biomarkers in neurodegenerative diseases course-a joint PhD student course at University College London and University of Gothenburg. Alzheimer's Research & Therapy. 12: 20. PMID 32111242 DOI: 10.1186/S13195-020-00586-6 |
0.48 |
|
| 2020 |
Westwood S, Baird AL, Anand SN, Nevado-Holgado AJ, Kormilitzin A, Shi L, Hye A, Ashton NJ, Morgan AR, Bos I, Vos SJB, Baker S, Buckley NJ, Ten Kate M, Scheltens P, et al. Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer's Disease Multimodal Biomarker Discovery Cohort. Journal of Alzheimer's Disease : Jad. PMID 31985466 DOI: 10.3233/Jad-190434 |
0.682 |
|
| 2020 |
Simrén J, Ashton NJ, Blennow K, Zetterberg H. An update on fluid biomarkers for neurodegenerative diseases: recent success and challenges ahead. Current Opinion in Neurobiology. 61: 29-39. PMID 31838254 DOI: 10.1016/j.conb.2019.11.019 |
0.513 |
|
| 2019 |
Ashton NJ, Ide M, Zetterberg H, Blennow K. Salivary Biomarkers for Alzheimer's Disease and Related Disorders. Neurology and Therapy. 8: 83-94. PMID 31833026 DOI: 10.1007/s40120-019-00168-1 |
0.451 |
|
| 2019 |
Ashton NJ, Suárez-Calvet M, Heslegrave A, Hye A, Razquin C, Pastor P, Sanchez-Valle R, Molinuevo JL, Visser PJ, Blennow K, Hodges AK, Zetterberg H. Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers. Alzheimer's Research & Therapy. 11: 94. PMID 31779670 DOI: 10.1186/S13195-019-0545-5 |
0.506 |
|
| 2019 |
Vogels T, Leuzy A, Cicognola C, Ashton NJ, Smolek T, Novak M, Blennow K, Zetterberg H, Hromadka T, Zilka N, Schöll M. Propagation of Tau Pathology: Integrating Insights From Postmortem and In Vivo Studies. Biological Psychiatry. PMID 31735253 DOI: 10.1016/J.Biopsych.2019.09.019 |
0.416 |
|
| 2019 |
Benedet AL, Ashton NJ, Pascoal TA, Leuzy A, Mathotaarachchi S, Kang MS, Therriault J, Savard M, Chamoun M, Schöll M, Zimmer ER, Gauthier S, Labbe A, Zetterberg H, Blennow K, et al. Plasma neurofilament light associates with Alzheimer's disease metabolic decline in amyloid-positive individuals. Alzheimer's & Dementia (Amsterdam, Netherlands). 11: 679-689. PMID 31673598 DOI: 10.1016/J.Dadm.2019.08.002 |
0.533 |
|
| 2019 |
Chatterjee P, Zetterberg H, Goozee K, Lim CK, Jacobs KR, Ashton NJ, Hye A, Pedrini S, Sohrabi HR, Shah T, Asih PR, Dave P, Shen K, Taddei K, Lovejoy DB, et al. Plasma neurofilament light chain and amyloid-β are associated with the kynurenine pathway metabolites in preclinical Alzheimer's disease. Journal of Neuroinflammation. 16: 186. PMID 31601232 DOI: 10.1186/s12974-019-1567-4 |
0.522 |
|
| 2019 |
Shi L, Westwood S, Baird AL, Winchester L, Dobricic V, Kilpert F, Hong S, Franke A, Hye A, Ashton NJ, Morgan AR, Bos I, Vos SJB, Buckley NJ, Kate MT, et al. Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 31495601 DOI: 10.1016/J.Jalz.2019.06.4951 |
0.604 |
|
| 2019 |
Kim M, Snowden S, Suvitaival T, Ali A, Merkler DJ, Ahmad T, Westwood S, Baird A, Proitsi P, Nevado-Holgado A, Hye A, Bos I, Vos S, Vandenberghe R, Teunissen C, ... ... Ashton N, et al. Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 31078433 DOI: 10.1016/J.Jalz.2019.03.004 |
0.641 |
|
| 2019 |
Startin CM, Ashton NJ, Hamburg S, Hithersay R, Wiseman FK, Mok KY, Hardy J, Lleó A, Lovestone S, Parnetti L, Zetterberg H, Hye A, Strydom A. Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer's disease. Alzheimer's Research & Therapy. 11: 26. PMID 30902060 DOI: 10.1186/S13195-019-0477-0 |
0.641 |
|
| 2019 |
Ashton NJ, Nevado-Holgado AJ, Barber IS, Lynham S, Gupta V, Chatterjee P, Goozee K, Hone E, Pedrini S, Blennow K, Schöll M, Zetterberg H, Ellis KA, Bush AI, Rowe CC, et al. A plasma protein classifier for predicting amyloid burden for preclinical Alzheimer's disease. Science Advances. 5: eaau7220. PMID 30775436 DOI: 10.1126/Sciadv.Aau7220 |
0.636 |
|
| 2019 |
Ashton NJ, Leuzy A, Lim YM, Troakes C, Hortobágyi T, Höglund K, Aarsland D, Lovestone S, Schöll M, Blennow K, Zetterberg H, Hye A. Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration. Acta Neuropathologica Communications. 7: 5. PMID 30626432 DOI: 10.1186/S40478-018-0649-3 |
0.636 |
|
| 2018 |
Westwood S, Baird AL, Hye A, Ashton NJ, Nevado-Holgado AJ, Anand SN, Liu B, Newby D, Bazenet C, Kiddle SJ, Ward M, Newton B, Desai K, Tan Hehir C, Zanette M, et al. Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [F]-Flutemetamol PET Scan Result. Frontiers in Aging Neuroscience. 10: 409. PMID 30618716 DOI: 10.3389/Fnagi.2018.00409 |
0.657 |
|
| 2018 |
Schöll M, Maass A, Mattsson N, Ashton NJ, Blennow K, Zetterberg H, Jagust W. Biomarkers for tau pathology. Molecular and Cellular Neurosciences. PMID 30529601 DOI: 10.1016/J.Mcn.2018.12.001 |
0.423 |
|
| 2018 |
Leuzy A, Heurling K, Ashton NJ, Schöll M, Zimmer ER. Detection of Alzheimer's Disease. The Yale Journal of Biology and Medicine. 91: 291-300. PMID 30258316 |
0.56 |
|
| 2018 |
Ashton NJ, Ide M, Schöll M, Blennow K, Lovestone S, Hye A, Zetterberg H. No association of salivary total tau concentration with Alzheimer's disease. Neurobiology of Aging. 70: 125-127. PMID 30007161 DOI: 10.1016/J.Neurobiolaging.2018.06.014 |
0.611 |
|
| 2018 |
Ashton NJ, Schöll M, Heurling K, Gkanatsiou E, Portelius E, Höglund K, Brinkmalm G, Hye A, Blennow K, Zetterberg H. Update on biomarkers for amyloid pathology in Alzheimer's disease. Biomarkers in Medicine. PMID 29902934 DOI: 10.2217/Bmm-2017-0433 |
0.538 |
|
| 2016 |
Westwood S, Leoni E, Hye A, Lynham S, Khondoker MR, Ashton NJ, Kiddle SJ, Baird AL, Sainz-Fuertes R, Leung R, Graf J, Hehir CT, Baker D, Cereda C, Bazenet C, et al. Blood-Based Biomarker Candidates of Cerebral Amyloid Using PiB PET in Non-Demented Elderly. Journal of Alzheimer's Disease : Jad. PMID 27031486 DOI: 10.3233/Jad-151155 |
0.663 |
|
| 2015 |
Ashton NJ, Kiddle SJ, Graf J, Ward M, Baird AL, Hye A, Westwood S, Wong KV, Dobson RJ, Rabinovici GD, Miller BL, Rosen HJ, Torres A, Zhang Z, Thurfjell L, et al. Blood protein predictors of brain amyloid for enrichment in clinical trials? Alzheimer's & Dementia (Amsterdam, Netherlands). 1: 48-60. PMID 27239491 DOI: 10.1016/J.Dadm.2014.11.005 |
0.597 |
|
| 2014 |
Hye A, Riddoch-Contreras J, Baird AL, Ashton NJ, Bazenet C, Leung R, Westman E, Simmons A, Dobson R, Sattlecker M, Lupton M, Lunnon K, Keohane A, Ward M, Pike I, et al. Plasma proteins predict conversion to dementia from prodromal disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 10: 799-807.e2. PMID 25012867 DOI: 10.1016/J.Jalz.2014.05.1749 |
0.623 |
|
| 2012 |
Bhamra MS, Ashton NJ. Finding a pathological diagnosis for Alzheimer's disease: are inflammatory molecules the answer? Electrophoresis. 33: 3598-607. PMID 23161254 DOI: 10.1002/elps.201200161 |
0.508 |
|
| Show low-probability matches. |